Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23600272 | 1.00 | SLC6A9 (0.34) | SLC6A9MAPT | |
| SCHEMBL25890082 | 0.83 | — | — | |
| SCHEMBL12741435 | 0.83 | SLC6A9 (0.33) | SLC6A9 | |
| SCHEMBL20794150 | 0.79 | GBA2 (0.35) | SLC6A9 | |
| SCHEMBL11992652 | 0.79 | MAPT (0.32) | MAPT | |
| SCHEMBL22450550 | 0.78 | — | — | |
| SCHEMBL13994664 | 0.77 | — | — | |
| SCHEMBL11190195 | 0.77 | SLC6A9 (0.31) | SLC6A9 | |
| SCHEMBL25978950 | 0.77 | SLC6A9 (0.31) | SLC6A9 | |
| SCHEMBL11780217 | 0.76 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218622-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-07-14 | — | — | US | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | SLC6A9 4209/4885MAPT 2954/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | SLC6A9 479/4885MAPT 4106/4885 |
| US-20220218622-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | NPC1L1, PLA2G4A, PLA2G2A | SLC6A9 2471/4885MAPT 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.